About Fermenta Biotech Ltd (FBL) - History
Fermenta Biotech Ltd (FBL), incepted under the auspices of Duphar Interfran Ltd (now known as DIL Ltd.), is the brainchild of late Mr. Vasant Kumar Datla.Established in 1986, FBL pioneered the manufacture of Penicillin G Amidase enzyme in India; it emerged as the leader in enzyme technologies for beta lactam (β-lactam) synthesis.
FBL now manufactures and supplies Vitamin D3 (the only manufacturer and supplier in India and among the top few manufacturers in the world) and constantly looks for value addition. FBL manufactures cholecalciferol also know as Vitamin D3 for further applications in global pharmaceutical, food, veterinary and feed industries (premix); cholecalciferol solutions for use in human food supplements; Vitamin D3 resin in oil and Vitamin D3 500 feed grade for use in animal feed supplements; and activated dimethicone powder (Silicon Powder) for antiflatulent use.....
From a pioneer of Penicillin G Amidase (PGA), FBL commercialised new and improved Novel Penicillin G Acylase (NPGA) for the synthesis of Amoxicillin, Cephalexin and developed platform for other Cephalasporins (Cefaclor, Cephadroxil etc). FBL also offers superior Candida antarctica lipase B or CAL B Lipase in both immobilized and free enzyme for various applications ranging from Chiral chemistry to Biofuel (Green Chemistry). FBL offers proprietery immobilization platform, DILBEADS for immobilized enzyme development.
FBL provides customized environmental biotech solutions through consultancy, supply of suitable biotech products and services in three segments – sewage treatment plant (STP), lake and pond bioremediation and oil remediation.
FBL is headquartered in Thane and is proximate to India’s financial capital, Mumbai. FBL’s APIs are manufactured in its Mandi facility in Himachal Pradesh and Dahej facility in Gujarat. FBL’s research and development facilities are located in Thane. FBLs pan-global presence extends across more than 50 countries (USA, UK, Germany, Belgium, The Netherlands, China, Brazil, Spain, France, Mexico, Switzerland, Turkey, Saudi Arabia, Israel, New Zealand and Sri Lanka, among others). FBL has emerged as a dependable supplier to more than 300 companies across India.
Today FBL has become a multifaceted organization with a high degree of focus on research, development and product delivery in the field of biotechnology, pharmaceutical and environmental solutions.
1986 : Established as Fermenta Biotech Ltd (erstwhile Fermenta Pharma Biodil Ltd)
1987 : Pioneered the launch of immobilised Penicillin G Acylase catalyst (Fermase PATM 250) for beta-lactam intermediates
1988 : Launched improved enzyme catalyst PGA white (Fermase PATM 750) for beta-lactam intermediates
2004 : Commenced manufacturing of Cholecalciferol (Vitamin D3), Isoxsuprine HCl and Phenyramidol HCI
2005 : Launched improved enzyme catalyst PGA white (Fermase PATM 750) for beta-lactam intermediates | Introduced R-oxynitrilase (Fermase OXTM) for chiral synthesis
2006 : Introduced DilbeadsTM, oxirane polymer beads for enzyme immobilisation
| Launched PGA catalyst blend (Fermase PATM 450) for cephalosporin intermediates
2007 : Invested to scale up capacities in preparation to enter export markets
| Launched silicon oil powder | Received Kosher certification for Vitamin D3
2008 : Received Halal certification for Vitamin D3
2009 : Launched novel Penicillin G Acylase (NPGA) for beta-lactam antibiotic synthesis (e.g. Amoxicillin) | Obtained CEP certification for Vitamin D3 from EDQM | Initiated Vitamin D3 sales in export markets | Introduced Phenyramidol formulations in India
2011 : Completed the construction of the second facility at Dahej, Gujarat | Ventured into animal feed and oil supplements of vitamin D3
| Applied for Canadian DMF and US DMF 2012 Successfully completed US FDA inspection for dietary supplements at Kullu
| Commercialised novel Penicillin G Acylase (NPGA) Fermase PS 150 for major global customers
| Launched new and improved Penicilin G Acylase catalyst, Fermase PA 850
| Augmented Vitamin D3 resins capacity at Dahej
2013 : Launched new and improved novel Penicillin G Acylase (NPGA) Fermase PS 250 and Fermase C-200 for Amoxicillin and Cephalexin synthesis
| New enzyme platform developed for Cephalosporin antibiotics (eg. Cefaclor, Cefadroxil)
| Launched enhanced CAL B Enzyme catalyst, Fermase CAL B series (immobilised and free enzyme)
| Launched new and improved DILBEADS
2014 : Established fully integrated Vitamin D3 manufacturing processes
| Initiated commercial Production of Vitamin D3 100 CWD to cater to the untapped food and Dietary Nutraceutical Supplements (DNS) market
| Initiated launch of Phenyramidol formulations in African market